Cargando…
Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines
Docetaxel (DTX) is a mainstay in the treatment of metastatic prostate cancer. Failure of DTX therapy is often associated with multidrug resistance caused by overexpression of efflux membrane transporters of the ABC family such as the glycoprotein ABCB1. This study investigated multiple approaches ta...
Autores principales: | Linke, Dinah, Donix, Lukas, Peitzsch, Claudia, Erb, Holger H. H., Dubrovska, Anna, Pfeifer, Manuel, Thomas, Christian, Fuessel, Susanne, Erdmann, Kati |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820728/ https://www.ncbi.nlm.nih.gov/pubmed/36614114 http://dx.doi.org/10.3390/ijms24010666 |
Ejemplares similares
-
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines
por: Donix, Lukas, et al.
Publicado: (2022) -
Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
por: Erdmann, Kati, et al.
Publicado: (2017) -
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer
por: Erb, Holger H. H., et al.
Publicado: (2020) -
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
por: Lima, Thiago S., et al.
Publicado: (2022) -
Quercetin Inhibits Lef1 and Resensitizes Docetaxel-Resistant Breast Cancer Cells
por: Prieto-Vila, Marta, et al.
Publicado: (2020)